Cost-effectiveness of human papillomavirus vaccination in Jordan: A modelling study
Single-dose HPV vaccination could prevent thousands of cervical cancers in Jordan over ten years, likely saving money while saving lives.
This modeling study demonstrates that a decade of single-dose HPV vaccination in Jordan could prevent over 2200 cervical cancer cases and 1200 deaths, with Cecolin being highly likely cost-saving (97%) and Cervarix achieving greater impact at cost-effective margins. The findings directly inform Jordanian national immunization policy and provide a replicable model for MENA-region cervical cancer prevention.
What the study was
- Study design
- Health economic modelling study (lifetime cohort simulation)
- Population
- Girls aged 12 years in Jordan targeted for single-dose HPV vaccination 2026–2035
- Category
- Prevention
- Maturity
- Validated
- Journal
- Vaccine
Why it surfaced
Well-executed health economic model with policy-ready conclusions; directly actionable for Jordan/MENA HPV vaccination program decisions; cervical cancer prevention with near-term population impact.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.